|
|
|
|
|
Legal status
Patent revoked (after opposition at EPO)
| (51) | INT.CL. | A61K 9/20 | (2006.01) |
| A61K 9/28 | (2006.01) | ||
| A61K 31/7068 | (2006.01) |
| (11) | Number of the document | 2695609 |
| (13) | Kind of document | T |
| (96) | European patent application number | 13182721.4 |
| Date of filing the European patent application | 2009-05-14 | |
| (97) | Date of publication of the European application | 2014-02-12 |
| (45) | Date of publication and mention of the grant of the patent | 2019-12-11 |
| (46) | Date of publication of the claims translation | 2020-02-10 |
| (30) | Number | Date | Country code |
| 53609 P | 2008-05-15 | US | |
| 201145 P | 2008-12-05 | US | |
| 157875 P | 2009-03-05 | US |
| (72) |
Etter, Jeffrey B., US
Lai, Mei, US
Backstrom, Jay T., US
|
| (73) |
Celgene Corporation ,
Route 206 & Province Line Road, Princeton, NJ 08543,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Per burną vartojamos citidino analogų kompozicijos ir jų panaudojimo būdai |
| Oral formulations of cytidine analogs and methods of use thereof |
| Payment date | Validity (years) | Amount | |
| 2025-04-02 | 17 | 347.00 EUR |
| Patent revoked (after opposition at EPO) | ||
| Invalidation date | 2025-06-03 |